Imfinzi® (durvalumab)

BL 761069

Imfinzi® (durvalumab)

BL 761069

U.S. License Holder:

AstraZeneca UK Ltd.

Date of License:

May-01-2017

Last Update:

May-15-2022

approved_indications FDA-Approved Indications

IMFINZI (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:

For the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy;

In combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-01028 (D. Del.)

U.S. Patent Nos.
9,402,899 (Immunopotentiative Composition)

Plaintiffs
Bristol-Myers Squibb Co.; E.R. Squibb and Sons LLC; Ono Pharmaceutical Co., Ltd.; Tasuku Honjo

Defendants
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited

Status
Stipulated Dismissal

BPCIA
N

1:22-cv-00346 (D. Del.)

U.S. Patent Nos.
9,580,505 (Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) 9,580,507 (Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) 10,138,299 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,594 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,595 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,266,596 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,308,714 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling) 10,323,092 (Cancer Immunotherapy by Disrupting PD-1 / PD-L1 Signaling)

Plaintiffs
Bristol-Myers Squibb Co.; E.R. Squibb and Sons, LLC

Defendants
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited

Status
Case Ongoing

BPCIA
N

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha